White blood cells and/or neutrophils in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils.

White blood cells and/or neutrophils in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils.

A dusted pet food kibble and a process for dusting a pet food kibble comprising providing a pet food kibble in the form of a core matrix, providing a powder comprising a first component that can comprise an active ingredient, such as Probiotic microorganism particles, and dusting the powder onto the pet food kibble to form a dusted kibble. The dusting can occur substantially free of a binder. An animal feed comprising a kibble in the form of a core dusted with active ingredients.

A dusted pet food kibble and a process for dusting a pet food kibble comprising providing a pet food kibble in the form of a core matrix, providing a powder comprising a first component that can comprise an active ingredient, such as Probiotic microorganism particles, and dusting the powder onto the pet food kibble to form a dusted kibble. The dusting can occur substantially free of a binder. An animal feed comprising a kibble in the form of a core dusted with active ingredients.

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

A premix is disclosed. The premix includes a nitrate compound and salts thereof in the amount of greater than about 50% by weight of the premix. The premix also includes vitamins and trace minerals. The premix is formulated for use in at least one of a gestation or lactation phase of an animal and in an amount of less than about five percent by weight (5.0 wt %) inclusion per metric ton of the premix. A supplement for an animal feed for feeding during at least one of an animal's gestation phase and/or lactation phase is also disclosed. A method for feeding an animal is also disclosed.

A premix is disclosed. The premix includes a nitrate compound and salts thereof in the amount of greater than about 50% by weight of the premix. The premix also includes vitamins and trace minerals. The premix is formulated for use in at least one of a gestation or lactation phase of an animal and in an amount of less than about five percent by weight (5.0 wt %) inclusion per metric ton of the premix. A supplement for an animal feed for feeding during at least one of an animal's gestation phase and/or lactation phase is also disclosed. A method for feeding an animal is also disclosed.

The present invention relates to a carrier for facilitating the oral ingestion of at least one active substance by animals, characterized in that it comprises: at least one bead comprising said at least one active substance, a gelled appetizing matrix surrounding said at least one bead, the pH of said matrix being less than 4, wherein the Aw (residual water) of said matrix and of said at least one bead is identical and from 0.4 to 0.9.

The present invention also relates to a method for preparing such a carrier, and also to the uses thereof.

The present invention also relates to a non-therapeutic method for feeding animals, in particular dogs and cats, by means of this carrier.

This disclosure pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. This disclosure also pertains to compositions comprising a calcium binder, particularly in combination with a chloride salt to supplement a diet of an animal, in particular, a pregnant animal.